AAD Member

In an analysis published in the Journal of Cosmetic Dermatology, researchers analyzed the relative efficacy of minoxidil and finasteride — in varying dosages and administrative routes — on change in total hair density at 24 weeks in women with pattern hair loss. . Researchers reported a significant dosage effect in many regimens. For example, 5% topical minoxidil solution at 1 mL twice a day for 24 weeks was significantly more efficacious than 5% topical minoxidil solution at 1 mL once a day for 24 weeks. . Likewise, 5% topical minoxidil solution administered at 1mL twice daily for 24 weeks was significantly more efficacious than 2% topical minoxidil solution administered at 1 mL twice a day for 24 weeks. . Researchers also found higher doses of finasteride to be more efficacious; 5 mg of finasteride once a day for 24 weeks was far more effective than 1 mg finasteride once a day for 24 weeks. . Visit the link in our bio to learn more about the results in #DermWorldWeekly .

@SeemalRDesaiMD shares his worldwide journey of what life entails as the president of the American Academy of Dermatology. . In the latest edition of “Dr. Desai on Your Side”, we get a behind-the-scenes look at what he accomplished in just one month on behalf of the Academy, the specialty, and most importantly—our members. . #aadmember #boardcertifieddermatologist #faadermatologist

Check out the teledermatology course in the AAD Learning Center: "Making Teledermatology Work for You: Practice Integration, Training, and Coding." . Visit the link in our bio to explore the four modules that cover patient guidance for telehealth visits, guidance for clinicians and staff, strategies for preventing and addressing potential pitfalls, plus valuable insights into coding and reimbursement.

University of Connecticut dermatology residents Neelesh Patrick Jain, MD, PGY-4, and Christian Gronbeck, MD, PGY-3, and dermatology program director Steven Brett Sloan, MD, FAAD, created this new Boards Fodder study chart on suture techniques. . Visit the link in our bio to download this chart and dozens more for free in the Boards Fodder archive from #DermWorld Directions in Residency.

The AAD Board of Directors want to share with you the top 5 reasons why you should join the Academy in Seattle this August for #aadinnovation2024 ! . Visit aad.org/ia24 to learn more about this exciting event and register today! . @seemalrdesaimd @drsusantaylor @drlindyfox @doctorcyndi @passionfordermatology

Join the AAD in Seattle this August for the educational event of the summer! 🌟 Learn about the business of dermatology (including branding, social media, product development, marketing, and more), how to implement AI in your dermatology practice, build your leadership skills, and incorporate innovative techniques from across the specialty. . Visit /IA24 or click the link in our bio to register today! #AADinnovation2024

The AAD social media correspondents shared tons of valuable information with the public for #SkinCancerAwarenessMonth as part of the Academy’s #YourDermatologistKnows consumer strategy. . AAD members can visit aad.org/your-dermatologist-knows to learn more!

A double-blind, placebo-controlled randomized trial published in JAMA Dermatology evaluated the efficacy of low-dose oral minoxidil versus topical minoxidil in treating patients with androgenetic alopecia. . Participants were randomized into two groups: oral minoxidil, 5 mg daily and topical placebo solution; or 1 mL of topical minoxidil, 5% twice daily and oral placebo for 24 weeks. . After 24 weeks, no significant difference in hair density was observed between the two groups, with both oral and topical minoxidil demonstrating comparable levels of improvement regarding hair density on the hairline and vertex. . The oral minoxidil group had a higher rate of hypertrichosis (49% vs. 25%) and headache (14%). According to the study authors, oral minoxidil is well-tolerated but does not demonstrate superiority over topical minoxidil in treating male patients with androgenetic alopecia. . Visit the link in our bio to learn more in the AAD's #DermWorldWeekly .

A research letter published in @JAADjournals investigated reported dermatologic adverse events associated with semaglutide, a glucagon-like peptide-1 agonist used to induce weight loss and improve glycemic control in type II diabetes. . A total of 22 articles described semaglutide-associated dermatologic adverse events in 255 patients. Injection site reactions occurred in 3.5% of patients, which was lower than the rate in the placebo and comparator groups. . Oral administration of semaglutide 50 mg was associated with altered skin sensations, such as dysesthesia, hyperesthesia, neuralgia, pain of the skin, paresthesia, sensitive skin, and a skin burning sensation. . In addition, alopecia was reported in 6.9% of patients on oral semaglutide 50 mg weekly compared to 0.3% of patients taking the placebo; however, only 0.2% of patients on subcutaneous semaglutide 2.4 mg had alopecia compared to 0.5% on placebo. . Several case reports documented isolated cases of severe events, such as angioedema, bullous pemphigoid, dermal hypersensitivity, eosinophilic fasciitis, and leukocytoclastic vasculitis, that led to discontinuation of semaglutide. . According to the authors, “higher rates of alopecia and altered skin sensations were seen in individuals on oral semaglutide. Variations in dosage and administration routes could influence the types and severity of skin findings, underscoring the need for additional research.” . Visit the link in our bio to learn more in #DermWorldWeekly .

🔥Shielding our heroes: The American Academy of Dermatology partnered with @fdny and @fcsn_national to provide free skin cancer checks to nearly 300 NYC firefighters! . Learn more at: aad.org/firefighters 🚒

A study published in the @intjderm assessed outcomes in patients undergoing treatment for moderate to severe acne with either low-dose oral isotretinoin alone or isotretinoin plus desloratadine. . Both groups showed comparable improvements in acne severity at 12 weeks, but patients receiving low-dose isotretinoin plus desloratadine 5 mg/day reported significantly lower rates of pruritus and higher rates of satisfaction with treatment. Pruritus reported was 9.7% in the study versus 33.3% in the control group. . Also, 53.6% of participants reported “excellent” treatment satisfaction in the study group versus 36.6% in the control group. The authors concluded that the addition of desloratadine to isotretinoin has a role in reducing disease and therapy-related pruritus in acne and leads to improved patient satisfaction.

A patient presents with widespread, pruritic, scaly, and erythematous plaques of what appears to be tinea corporis. It may be routine to prescribe an antifungal cream or oral agent based on the visual clinical clues. . Dermatophyte infections (aka “ringworm” or tinea) have been around for a very long time, and dermatologists have extensive experience diagnosing and treating these infections. However, with increasing resistance to antifungal treatments, physicians may need to adjust their approach to treating dermatophytosis. . Dermatophytosis accounts for many outpatient visits due to fungal diseases, said Aditya K. Gupta, MD, PhD, MBA/HCM, MA, FECMM, FAAD, FRCPC, professor in the department of medicine at the University of Toronto. “We could see more patients being referred to specialists by primary care providers due to recurrent infections, and unlike bacterial infections, we have fewer treatment options for these newly emerged pathogenic fungi.” . “With the emergence of recalcitrant superficial skin infections, as leaders in this area of skin disease and experts on skin and skin health, we really do have a stake and a role in helping to understand this emerging problem,” said Avrom S. Caplan, MD, FAAD, assistant professor at NYU’s Grossman School of Medicine. . Read this #DermWorld cover story, plus new feature articles on: . ☑️ Recent changes to the clinical publication model ☑️ Staying compliant amid new policy changes ☑️ Managing contact allergies to botanicals ☑️ Measuring lesions and choosing appropriate excision codes ☑️ The evolution of telehealth after the pandemic . Visit the link in our bio to read the entire June issue today.